Daewoong Pharmaceutical is targeting the post-health checkup management market by supplying a ring-type ambulatory blood pressure monitor (ABPM) to the Korea Health Management Association.
On August 11, Daewoong Pharmaceutical announced that it has begun supplying the 'CART BP Pro' to 17 branches of the Korea Health Management Association nationwide.
This introduction allows the Korea Health Management Association to conduct 24-hour ambulatory blood pressure measurements for individuals who show abnormal blood pressure findings during health checkups. It is expected to provide more accurate blood pressure assessments and post-management by monitoring blood pressure changes during daily activities and sleep.
Blood pressure readings taken in a clinical setting can vary based on the measurement environment or timing, making it difficult to confirm conditions like white coat hypertension, masked hypertension, and nocturnal hypertension with office readings alone. The 24-hour ambulatory blood pressure test is utilized for these cases. The recently revised '2026 Hypertension Management Guidelines' also recommend ambulatory blood pressure monitoring for diagnosing hypertension and evaluating treatment effectiveness.
The CART BP Pro, developed by Skylabs and supplied by Daewoong Pharmaceutical, is a ring-type cuffless ambulatory blood pressure monitor. It measures 24-hour blood pressure changes based on photoplethysmography (PPG) and is designed to reduce the discomfort of repeated arm compression associated with traditional cuff devices.
The CART BP Pro was included in the national health insurance coverage in June 2024 and is currently used for over 240,000 ambulatory blood pressure measurements across more than 1,800 medical institutions in South Korea, including Seoul National University Hospital, Severance Hospital, Samsung Medical Center, and Seoul St. Mary's Hospital.
With this supply, Daewoong Pharmaceutical plans to expand its post-management model, enabling precise confirmation and continuous management of individuals with abnormal blood pressure findings after health checkups.
Lee Chang-jae, CEO of Daewoong Pharmaceutical, stated, "This introduction signifies the expansion of the CART BP Pro's application beyond hospitals and clinics into the health checkup and preventive care sectors. We aim to contribute to the advancement of the domestic health checkup system and the improvement of public health through digital healthcare."
Meanwhile, the company is exploring the potential for expanding various digital healthcare areas, including the development of more sophisticated health management and predictive models, based on the data-driven service experience gained from operating its digital health product line.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.